<DOC>
	<DOCNO>NCT00778596</DOCNO>
	<brief_summary>Study purpose : To investigate whether ALT rebound follow corticosteroid prim enhances response telbivudine therapy . Efficacy assessment : The primary endpoint 1-year HBe-Ag seroconversion rate without prednisolone priming . Data analysis : A summary table present frequency table categorical variable number , percentage , whereas descriptive table continuous variable number , mean ± SD median ( minimum , maximum ) . All statistical assessment two-sided evaluated significance level 0.05 . Continuous variable analyze use t-test , ANOVA , categorical variable analyze use chi-square Fisher 's exact test . A non-parametric method , Wilcoxon rank-sum sign-rank test conduct continuous , categorical variable data far normal distribution .</brief_summary>
	<brief_title>Prednisolone Priming Study Patients With Chronic Hepatitis B</brief_title>
	<detailed_description>This Phase IV , multi-center , double-blinded , placebo control randomize study evaluate therapeutic effect telbivudine without prednisolone priming patient chronic hepatitis B . Patients allocate either group A B randomly . Group A : Patients initially receive 4-week course oral prednisolone ( 30 mg daily 3 week 15 mg daily 1 week ) . After rest period treatment 2 week , patient receive telbivudine therapy daily dose 600 mg 2 year . Patients ask come back clinic follow-up 6 month telbivudine treatment . Group B : Patients receive 4-week course placebo . After rest period treatment 2 week , patient receive telbivudine therapy daily dose 600 mg 2 year . Patients ask come back clinic follow-up 6 month telbivudine treatment . Eligible patient randomize prior first dose study medication . The visit patient receive first dose define study Baseline . Patients return clinic 3 , 4 , 6 , 10 , 14 , 18 , 30 , 44 , 58 , 72 , 86 , 98 , 110 , 116 , 122 , 128 134 week post-Baseline . At visit , routine clinical laboratory test , adverse event inquiry , clinical assessment perform . Serum sample HBV DNA analysis obtain 4 , 6 , 30 , 58 , 86 , 110 134 week . Serum sample HBV sequence obtain Screening Week 110 ( upon early termination study ) . Complete physical examination perform study visit evaluate adverse sign symptom report patient . Serum HBeAg , antibody HBeAg ( HBeAb ) , HBsAg , antibody HBsAg ( HBsAb ) obtain Screening , Baseline , Weeks 6 , 30 , 58 , 86 , 110 134 ( upon early termination study ) , protocol-required follow-up visit . Patients follow monthly 6 month discontinuation study drug ( ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Treatment naïve patient interferontreated patient 6 month , oral antiviral agent treatment ≦ 2 week treatment &lt; 3 month 1 year prior screen . 2 . Male female , 18 65 year age . 3 . Documented chronic hepatitis B define follow : Clinical history compatible compensate chronic hepatitis B. Detectable serum hepatitis B surface antigen ( HBsAg ) &gt; 6 month screen visit . Hepatitis B e antigen ( HBeAg ) positive &gt; 3 month . Serum HBV DNA &gt; 2x10^5 IU/mL raise serum ALT &gt; 2xULN &lt; 5xULN determine least 2 occasion 1 month apart screen within 3 month prescreen , raise serum ALT &gt; 2xULN &lt; 5xULN determine 1 month apart screen screen.4 . 4 . Liver biopsy show chronic hepatitis fibrosis stage ≦ 4 Ishak classification within 6 month fibrosis ≦ 4 6 12 month plus platelet count ≧ 150,000/mm3 noninvasive assessment ( fibroscan ARFI ) liver fibrosis exclude liver cirrhosis within 6 month . 5 . Willing able comply study drug regimen study requirement . 6 . Willing able provide write informed consent participate study . Patients exclude study follow reason : 1 . Pregnant nursing . 2 . Of reproductive potential ( men woman ) unwilling use doublebarrier method contraception ( i.e. , condom spermicide diaphragm spermicide ) . 3 . Coinfection hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , HIV . 4 . History clinical signs/symptoms hepatic decompensation portal hypertension , ascites , presence esophageal varix variceal bleeding , hepatic encephalopathy , spontaneous bacterial peritonitis . 5 . Liver cirrhosis ( Ishak fibrosis score 5 6 ) . 6 . Any medical condition require prolonged frequent use systemic acyclovir famciclovir ( e.g. , recurrent herpes virus infection ) . 7 . History hepatocellular carcinoma ( HCC ) finding suggestive possible HCC , suspicious focus image study elevate serum alphafetoprotein ( AFP ) level . A history treat malignancy HCC allowable patient 's malignancy complete remission , chemotherapy without additional surgical intervention , precede 3 year . 8 . One know primary secondary cause liver disease hepatitis B ( e.g. , alcoholism , nonalcoholic steatohepatitis , autoimmune hepatitis , malignancy hepatic involvement , hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's disease , congenital metabolic condition affect liver , congestive heart failure severe cardiopulmonary disease ) . Gilbert 's syndrome DubinJohnson syndrome exclude patient participation trial . 9 . History clinically evident pancreatitis . 10 . Currently abuse alcohol ( i.e. , average daily intake 40 g ethanol ) illicit drug history alcohol abuse illicit substance abuse within precede 2 year . Patients currently methadone maintenance treatment program NOT eligible . 11 . A medical condition require frequent prolong use systemic corticosteroid ( e.g. , severe asthma , severe arthritis autoimmune condition , organ transplantation , adrenal insufficiency ) . 12 . A medical condition require chronic prolong use potentially hepatotoxic drug ( dapsone , erythromycin , fluconazole , ketoconazole , rifampin , antituberculosis regimen , etc. ) . All drug must discontinue ≥ 30 day prior randomization . 13 . A medical condition require use nephrotoxic drug ( e.g. , aminoglycosides , amphotericin B , foscarnet , vancomycin , cyclosporine , tacrolimus , frequent nonsteroidal antiinflammatory drug ( NSAIDS ) aspirin [ administer daily one week schedule dose intended antiinflammatory therapy ] ) . All drug must discontinue ≥ 30 day prior randomization . 14 . Any concurrent medical psychosocial condition likely preclude compliance schedule evaluation protocol likely confound efficacy safety observation study . 15 . Enrolled planning enroll another clinical trial investigational agent participate study . 16 . Any following laboratory value Screening : Hemoglobin ( Hb ) &lt; 11 mg/dL men &lt; 10 mg/dL woman . Total white blood cell count ( WBC ) &lt; 2,500/mm3 . Absolute neutrophil count ( ANC ) &lt; 1,500/mm3 . Platelet count &lt; 75,000/mm3 . Serum albumin &lt; 3.2 g/dL . Total bilirubin ≥2 mg/dL direct bilirubin &gt; 50 % total bilirubin . Serum creatinine &gt; 1.0 x ULN . Alphafetoprotein ( AFP ) &gt; 50 ng/mL ( require evaluation , ruleout hepatocellular carcinoma ) Creatinine clearance ( CrCl ) &lt; 0.83 mL/sec ( &lt; 50 mL/min ) calculate laboratory use modify CockcroftGault method . Serum amylase lipase ³1.5 x ULN . Prothrombin time ( PT ) prolong &gt; 3 second International Normalized Ratio ( INR ) &gt; 1.5 , base upper limit normal ( ULN ) reference value , despite vitamin K administration . 17 . Use investigational drug within 30 day 5 halflives randomization , whichever longer . 18 . Systemic malignancy within 5 year . 19 . Previous treatment telbivudine . 20 . History hypersensitivity component either telbivudine formulation , drug similar chemical structure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Telbivudine</keyword>
	<keyword>Prednisolone</keyword>
</DOC>